Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disease which accounts for 50 % of all heart failure [1–3]. Currently, treatment for HFpEF not only focuses on improving heart failure symptoms with diuretics but also aims to enhance prognosis through the use of medications such as sodium-glucose cotransporter-2 inhibitor. Comorbidities in HFpEF is very common, including hypertension, diabetes, obesity, coronary artery disease, and chronic kidney disease, and the managing of these comorbidities is very important for the prognosis [4].
